MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
The DOI matches its Crossref record; 201 of the 201 references it cites were found in a registry or an index.
Abstract
The role of the ERK signalling pathway in cancer is thought to be most prominent in tumours in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive growth factor-independent ERK1 and ERK2 activation and thence inappropriate cell proliferation and survival. New drugs that inhibit RAF or MEK1 and MEK2 have recently been approved or are currently undergoing late-stage clinical evaluation. In this Review, we consider the ERK pathway, focusing particularly on the role of MEK1 and MEK2, the 'gatekeepers' of ERK1/2 activity. We discuss their validation as drug targets, the merits of targeting MEK1 and MEK2 versus BRAF and the mechanisms of action of different inhibitors of MEK1 and MEK2. We also consider how some of the systems-level properties (intrapathway regulatory loops and wider signalling network connections) of the ERK pathway present a challenge for the success of MEK1 and MEK2 inhibitors, discuss mechanisms of resistance to these inhibitors, and review their clinical progress.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The limited ef fi cacy observed for MEK inhibitors may involve adaptive feedback mechanisms through the reactivation of MAPK signalling caused by the blockade of ERK signalling [11 -13].”
In the citing paper
“Although RAS/RAF-mutated CRC has been targeted for the development of therapeutic inhibitors, they have been largely ineffective, likely due to complex resistance mechanisms such as intrinsic and adaptive resistance [5–12].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [5]
In the citing paper
“However, MEK inhibitors, used alone, have been largely ineffective, likely due to intrinsic and adaptive resistance mechanisms [5–7].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [5]
In the citing paper
“Previous studies demonstrated that the adaptive reactivation of MAPK signaling in the presence of a MEK inhibitor was mediated by the loss of MAPK-dependent negative feedback loops and the consequent induction of RTKs signaling (26, 53).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [53]
In the citing paper
“targeting of MEK alone is frequently hampered by adaptive resistance, which is complex and context-dependent, and can involve activation of various RTKs, including ERBB family, AXL, PDGFR-α, or FGFR1 (26, 53, 59–62).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [53]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
The ground state of embryonic stem cell self-renewal
Ying, Q.-L., Wray, J., Nichols, J., Batlle-Morera, L., Doble, B., Woodgett, J., Cohen, P., & Smith, A. (2008) · Nature · doi:10.1038/nature06968 · Cited by 3,442
Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., & Saltiel, A. R. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27489 · Cited by 3,393
Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase
Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.18623 · Cited by 3,015
Hauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Cited by
Items 101–200 of 615
Loss of DLG5 promotes breast cancer malignancy by inhibiting the Hippo signaling pathway
Liu, J., Li, J., Li, P., Wang, Y., Liang, Z., Jiang, Y., Li, J., Feng, C., Wang, R., Chen, H., et al. (2017) · Scientific Reports · doi:10.1038/srep42125 · Cited by 61
Feng, J., Lian, Z., Xia, X., Lu, Y., Hu, K., Zhang, Y., Liu, Y., Hu, L., Yuan, K., Sun, Z., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.10.023 · Cited by 71
Kirouac, D. C., Schaefer, G., Chan, J., Merchant, M., Orr, C., Huang, S.-M. A., Moffat, J., Liu, L., Gadkar, K., & Ramanujan, S. (2017) · npj Systems Biology and Applications · doi:10.1038/s41540-017-0016-1 · Cited by 60
“Yet despite the wealth of pre-clinical data posing MAPK as a critical oncogenic pathway, clinical activity has been minimal outside of melanoma.(53) In addition to the wellestablished robustness of the MAPK network due to feedback circuits and pathway cross-talk,(54) our results provide two critical explanations for t…”
ResultRobb, R. N., Yang, L., Shen, C., Wolfe, A. R., Webb, A., Zhang, X., Vedaie, M., Saji, M., Jhiang, S. M., Ringel, M. D., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3625 · Cited by 61
“Therefore, targeting downstream RAF, MEK, and ERK is being actively pursued in cancer therapeutics (4, 5).”
BackgroundPhase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia
Maiti, A., Naqvi, K. Z., Kadia, T. M., Borthakur, G. M., Takahashi, K., Bose, P., Daver, N. G., Patel, A. P., Alvarado, Y., Ohanian, M. N., et al. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.12.009 · Cited by 62
“146 inhibition.(4,9,23,24) Increased RasGRP1 and reduced p38 kinase activity have been implicated in MEK inhibitor resistance in AML cell lines with hyperactive RAS.”
InfluentialTrametinib in the treatment of multiple malignancies harboring MEK1 mutations
Lian, T., Li, C., & Wang, H. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101907 · Cited by 58
Activating mutations in MEK1 enhance homodimerization and promote tumorigenesis
Yuan, J., Ng, W. H., Tian, Z., Yap, J., Baccarini, M., Chen, Z., & Hu, J. (2018) · Science Signaling · doi:10.1126/scisignal.aar6795 · Cited by 63
Melorheostosis and Osteopoikilosis: A Review of Clinical Features and Pathogenesis
Wordsworth, B. P., & Chan, M. (2019) · Calcified Tissue International · doi:10.1007/s00223-019-00543-y · Cited by 65
Tomasovic, A., Brand, T., Schanbacher, C., Kramer, S., Hümmert, M. W., Godoy, P., Schmidt‐Heck, W., Nordbeck, P., Ludwig, J., Homann, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15505-4 · Cited by 63
Chu, J. Y., Dransfield, I., Rossi, A. G., & Vermeren, S. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.006 · Cited by 72
Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer
Matsuda, N., Lim, B., Wang, X., & Ueno, N. T. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1299707 · Cited by 68
“Phosphorylated MEK1 and MEK2 mediate the ERK pathway and subsequently activate a number of transcription factors.”
BackgroundTurnham, R. E., Smith, F. D., Kenerson, H. L., Omar, M. H., Golkowski, M., Garcia, I., Bauer, R., Lau, H.-T., Sullivan, K. M., Langeberg, L. K., et al. (2019) · eLife · doi:10.7554/elife.44187 · Cited by 61
Severe metabolic alterations in liver cancer lead to ERK pathway activation and drug resistance
Nwosu, Z. C., Piorońska, W., Battello, N., Zimmer, A. D., Dewidar, B., Han, M., Pereira, S., Blagojevic, B., Castven, D., Charlestin, V., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102699 · Cited by 62
“However, many patients who initially respond to therapies targeting the ERK pathway later develop drug resistance [3-5].”
BackgroundZheng, Z.-Y., Yang, P.-L., Li, R.-Y., Liu, L.-X., Xu, X., Liao, L., Li, X., Chu, M.-Y., Liu, P., Huang, Q., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.09.035 · Cited by 65
Acute myeloid leukemia – strategies and challenges for targeting oncogenic Hedgehog/GLI signaling
Aberger, F., Hutterer, E., Sternberg, C., del Burgo, P. J., & Hartmann, T. N. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-017-0163-4 · Cited by 58
Kotelnikova, E. A., Kiani, N. A., Messinis, D. E., Pertsovskaya, I., Pliaka, V., Bernardo-Faura, M., Rinas, M., Vila, G., Zubizarreta, I., Pulido-Valdeolivas, I., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818347116 · Cited by 71
“Due to the key involvement of the MAPK pathway in cancer (RAS, BRAF, CRAF, MEK1, or MEK2 mutations), MEK1 inhibitors like trametinib or cobimetinib have been approved for the treatment of BRAF-mutated melanoma and new ERK1 inhibitors are being actively sought (19).”
BackgroundHan, S., Shin, H., Lee, J., Liu, Z., Rabadán, R., Lee, J., Shin, J., Lee, C., Yang, H., Kim, D., et al. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0351-y · Cited by 60
Nakano, T. A., Rankin, A. W., Annam, A., Kulungowski, A. M., McCallen, L. M., Hill, L. R. S., & Chatfield, K. C. (2022) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2022.05.030 · Cited by 54
Jiang, M., Qiu, Z., Zhang, S., Fan, X., Cai, X., Xu, B., Li, X., Zhou, J., Zhang, X., Chu, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11359 · Cited by 54
“The extracellular signal-regulated kinases ERK1 and ERK2 (ERK 1/2) cascade was first discovered as a classical signal-transduction pathway of the MAPK family, which regulates various cellular processes in normal and cancer tissues [26, 27].”
BackgroundTokita, M., Chen, C., Chitayat, D. A., Macnamara, E. F., Rosenfeld, J. A., Hanchard, N. A., Lewis, A. M., Brown, C., Marom, R., Shao, Y., et al. (2018) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2018.06.005 · Cited by 60
Dual effects of active ERK in cancer: A potential target for enhancing radiosensitivity (Review)
Lu, Y., Liu, B., Liu, Y., Yu, X., & Cheng, G. (2020) · Oncology Letters · doi:10.3892/ol.2020.11684 · Cited by 59
“Various inhibitors for suppressing ERK signaling have been tested in preclinical and clinical investigations, including RAF inhibitors (vemurafenib, dabrafenib, LGX818, TAK-632, MLN2480 and PLX-4720), MEK inhibitors (trametinib, cobimetinib, MEK162, AZD6244, RO5126766, GDC-0623 and PD0325901) and ERK inhibitors (SCH77…”
MethodZhang, S., Huang, Q., Ji, T., Li, Q., & Hu, C. (2024) · Biomarker Research · doi:10.1186/s40364-024-00677-8 · Cited by 60
“MEK1 and MEK2 are components of downstream oncogenic RAS and RAF signaling pathways and are important mediators of malignant transformation and drug resistance [26].”
BackgroundTargeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges
Choucair, K., Imtiaz, H., Uddin, M. H., Nagasaka, M., Al-Hallak, M. N., Philip, P. A., El-Rayes, B., Pasche, B., & Azmi, A. S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02473-8 · Cited by 79
“205 – 211 The precise mechanisms underlying adaptive resistance to KRAS G12C inhibitors remain unclear: whether adaptive resistance is mediated by reactivation of mutant KRAS or activation/recruitment of wild-type KRAS remains a subject of debate.”
Sale, M. J., Balmanno, K., Saxena, J., Ozono, E., Wojdyla, K., McIntyre, R. E., Gilley, R., Woroniuk, A., Howarth, K. D., Hughes, G., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09438-w · Cited by 52
Self-citationIs the Canonical RAF/MEK/ERK Signaling Pathway a Therapeutic Target in SCLC?
Cristea, S., & Sage, J. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.04.018 · Cited by 54
Functional significance of co-occurring mutations in PIK3CA and MAP3K1 in breast cancer
Avivar‐Valderas, A., McEwen, R. K., Taheri‐Ghahfarokhi, A., Carnevalli, L. S., Hardaker, E. L., Maresca, M., Hudson, K., Harrington, E. A., & Cruzalegui, F. H. (2018) · Oncotarget · doi:10.18632/oncotarget.25118 · Cited by 50
“On the contrary, co-administration of AKT with MEK inhibitors [56] can attenuate the negative feedback, restore AKTi sensitivity and may ultimately provide therapeutic benefit for patients with concomitant PIK3CA/MAP3K1 mutations.”
BackgroundIavarone, C., Zervantonakis, I. K., Selfors, L. M., Palakurthi, S., Liu, J. F., Drapkin, R., Matulonis, U. A., Hallberg, D., Velculescu, V. E., Leverson, J. D., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0413 · Cited by 52
“The most upregulated phosphoprotein was MEK, consistent with inhibition of its catalytic activity, its phosphorylation by RAF proteins, and activation of feedback loops (37).”
BackgroundParadoxical activation of the protein kinase-transcription factor ERK5 by ERK5 kinase inhibitors
Lochhead, P. A., Tucker, J. A., Tatum, N. J., Wang, J., Oxley, D., Kidger, A. M., Johnson, V. P., Cassidy, M. A., Gray, N. S., Noble, M. E. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15031-3 · Cited by 57
Self-citationSu, Y., Li, X., Ma, J., Zhao, J., Liu, S., Wang, G., Edwards, H. J., Taub, J. W., Lin, H., & Ge, Y. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.11.022 · Cited by 54
“Further, PI3K/mTOR inhibition has been shown to cause compensatory ERK activation, resulting in cell survival [2, 4, 5].”
SHOC2 complex-driven RAF dimerization selectively contributes to ERK pathway dynamics
Boned del Río, I., Young, L. C., Sari, S., Jones, G. G., Ringham-Terry, B., Hartig, N., Rejnowicz, E., Lei, W., Bhamra, A., Surinova, S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902658116 · Cited by 50
Mathien, S., Tesnière, C., & Meloche, S. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000170 · Cited by 57
Laakkonen, J. P., Lähteenvuo, J., Jauhiainen, S., Heikura, T., & Ylä‐Herttuala, S. (2018) · Vascular Pharmacology · doi:10.1016/j.vph.2018.10.005 · Cited by 53
Research progress of MEK1/2 inhibitors and degraders in the treatment of cancer
Wang, C., Wang, H., Zheng, C., Liu, Z., Gao, X., Xu, F., Niu, Y., Zhang, L., & Xu, P. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113386 · Cited by 51
Zhao, Z., Xie, L., & Bourne, P. E. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179936 · Cited by 54
Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors
O’Connor, C. M., Leonard, D., Wiredja, D., Avelar, R. A., Wang, Z., Schlatzer, D., Bryson, B., Tokala, E., Taylor, S. E., Upadhyay, A., et al. (2020) · Oncogene · doi:10.1038/s41388-019-1012-2 · Cited by 48
Sato, H., Schoenfeld, A. J., Siau, E., Lu, Y. C., Tai, H., Suzawa, K., Kubota, D., Lui, A. J. W., Qeriqi, B., Mattar, M. S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3321 · Cited by 54
Ferrous Iron-Dependent Pharmacology
Gonciarz, R. L., Collisson, E. A., & Renslo, A. R. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.11.003 · Cited by 49
“Thus the significance of ferrous-iron dependent pharmacology in the context of mutant KRAS-driven malignancies could lie in the ability to achieve potent yet tolerable parallel and/or vertical pathway blockade, thus avoiding the inter- and intra-pathway signaling loops that enable tumor escape from single-agent blocka…”
BackgroundInsights into molecular mechanisms of chemotherapy resistance in cancer
Kar, A., Agarwal, S., Singh, A., Bajaj, A., & Dasgupta, U. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.101901 · Cited by 52
“MEK1 is a component of RAS-regulated RAF – MEK – ERK signaling pathway that enables nucleus and other organelles to receive signals from growth factor receptors that control proliferation, differentiation, survival, and invasion of cells [64].”
BackgroundXiong, D., Qiu, Y., Zhao, J., Zhou, Y., Lee, D., Gupta, S., Torres, M., Lü, W., Liang, S., Kang, J. J., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02428-4 · Cited by 60
“Phosphorylated MEK1 acts as upstream activators to phosphorylate ERK1/2 kinase activities in the MAPK cascade 96 .”
Ochiai, A., Miyata, S., Iwase, M., Shimizu, M., Inoue, J., & Sato, R. (2016) · Scientific Reports · doi:10.1038/srep24940 · Cited by 46
Nishiguchi, G., Rico, A. C., Tanner, H. R., Aversa, R. J., Taft, B. R., Subramanian, S., Setti, L., Burger, M. T., Wan, L., Tamez, V., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01862 · Cited by 47
Kim, Y., Tsang, T., Anderson, G. R., Posimo, J. M., & Brady, D. C. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-1784 · Cited by 51
“The limited clinical durability of the combination has bolstered research aimed at additional combination strategies to forestall resistance development, targetingmultiple signaling pathways capable of driving resistance, or exploring alternative pharmacologic accessible nodes within the MAPK pathway (4, 10, 11).”
BackgroundCorcoran, R. B., Do, K. T., Kim, J. E., Cleary, J. M., Parikh, A. R., Yeku, O. O., Xiong, N., Weekes, C. D., Veneris, J., Ahronian, L. G., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3135 · Cited by 46
“Similarly, other studies have suggested a role for BCL-xL and/or other antiapoptotic proteins in the apoptotic response to MAPK pathway inhibition (14).”
Molecular changes associated with vascular malformations
Fereydooni, A., Dardik, A., & Nassiri, N. (2019) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2018.12.033 · Cited by 45
MEK inhibition suppresses B regulatory cells and augments anti-tumor immunity
Yarchoan, M. M., Mohan, A. A., Dennison, L., Vithayathil, T., Ruggieri, A. N., Lesinski, G. B., Armstrong, T. D., Azad, N. S., & Jaffee, E. M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0224600 · Cited by 45
Endothelial MAP2K1 mutations in arteriovenous malformation activate the RAS/MAPK pathway
Smits, P. J., Konczyk, D. J., Sudduth, C. L., Goss, J. A., & Greene, A. K. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.06.022 · Cited by 45
“The FDA approved MEK1(MAP2K1) inhibitor Trametinib has been used to treat neoplasms that contain activating MAP2K1 mutations [14] and has been used off-label to treat AVMs [15].”
BackgroundThe State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies
García-Sampedro, A., Gaggia, G., Ney, A., Mahamed, I., & Acedo, P. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040566 · Cited by 50
The role of the RAS pathway in iAMP21-ALL
Ryan, S. L., Matheson, E. C., Großmann, V., Sinclair, P. B., Bashton, M., Schwab, C. J., Towers, W. G., Partington, M. W., Elliott, A., Minto, L., et al. (2016) · Leukemia · doi:10.1038/leu.2016.80 · Cited by 46
Shao, W., Mishina, Y. M., Feng, Y., Caponigro, G., Cooke, V. G., Rivera, S., Wang, Y., Shen, F., Korn, J. M., Mathews Griner, L. A., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2033 · Cited by 44
Kelly, M. R., Kostyrko, K., Han, K., Mooney, N. A., Jeng, E. E., Spees, K., Dinh, P. T., Abbott, K. L., Gwinn, D. M., Sweet-Cordero, E. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1274 · Cited by 44
Ren, L.-X., Qi, J., Zhao, A., Shi, B., Zhang, H., Wang, D., & Yang, Z. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02020-9 · Cited by 44
“Both MEK1 and MEK2 activate Erk/MAP kinase related to cell growth and differentiation [29].”
BackgroundInformation Transfer in Gonadotropin-releasing Hormone (GnRH) Signaling
Garner, K. L., Perrett, R. M., Voliotis, M., Bowsher, C., Pope, G. R., Pham, T., Caunt, C. J., Tsaneva-Atanasova, K., & McArdle, C. A. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.686964 · Cited by 43
Self-citationZhao, B., Dierichs, L., Gu, J., Trajkovic‐Arsic, M., Hilger, R. A., Savvatakis, K., Vega-Rubín-de-Celis, S., Liffers, S., Peña‐Llopis, S., Behrens, D., et al. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-0246-7 · Cited by 44
MEK1/2 Inhibition Promotes Macrophage Reparative Properties
Long, M. E., Eddy, W. E., Gong, K.-Q., Lovelace-Macon, L., McMahan, R. S., Charron, J., Liles, W. C., & Manicone, A. M. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1601059 · Cited by 42
“The MAPKs MEK1 (Mek1) and MEK2 (Mek2) participate in intracellular signaling networks and exert control on downstream effector molecules ERK1 and ERK2 via MEK1/2dependent serine and tyrosine phosphorylation (12).”
BackgroundRegulation of Signal Transduction by DJ-1
Oh, S. E., & Mouradian, M. M. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6583-5_8 · Cited by 49
Li, J., Xiao, Q., Bao, Y., Wang, W., Goh, J. Y., Wang, P., & Yu, Q. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1624113 · Cited by 46
“AZD6244 is a second generation MEK inhibitors and is currently at the early stage of clinical development [19,20].”
BackgroundLu, Y., Liu, H., Yang, K., Mao, Y., Meng, L., Yang, L., Ouyang, G., & Liu, W. (2022) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2100182 · Cited by 47
“In addition to promoting cancer directly by se‐ creting cytotoxins, related metabolites such as bile acids (Jia et al., 2019), polyamines, and specific enzymes released by the intestinal microflora can promote the production of GC and GPC. Bile acids can induce the canceration of gastric epithelial cells through extra…”
BackgroundInfluentialMitochondrial Metabolism in Melanoma
Huang, C. Y., Radi, R., & Arbiser, J. L. (2021) · Cells · doi:10.3390/cells10113197 · Cited by 42
“However, although MAP2K1/2 seems an appealing target with unique allosteric binding sites, the fact that these kinases are in all cells would likely lead to excessive effects on normal cells as well [180].”
BackgroundPan‐cancer RNA‐seq data stratifies tumours by some hallmarks of cancer
Frost, F. G., Cherukuri, P. F., Milanovich, S. J., & Boerkoel, C. F. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14746 · Cited by 50
High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer
Mizuno, S., Ikegami, M., Koyama, T., Sunami, K., Ogata, D., Kage, H., Yanagaki, M., Ikeuchi, H., Ueno, T., Tanikawa, M., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0302 · Cited by 46
“Currently availableMEKis exhibit high selectivity because they are not ATP-competitive, rather they bind to an allosteric site adjacent to the ATP pocket (25).”
ETS‐targeted therapy: can it substitute for MEK inhibitors?
Tetsu, O., & McCormick, F. P. (2017) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0147-4 · Cited by 45
“The compounds inhibit not only the ability of MEK1 and MEK2 to elevate ERK1 and ERK2, but also impair the ability of RAF to phosphorylate MEK1 and MEK2 by disrupting the conformation of the activation loop of MEK1 and MEK2.”
BackgroundInfluentialCancer Genetic Network Inference Using Gaussian Graphical Models
Zhao, H., & Duan, Z.-H. (2019) · Bioinformatics and Biology Insights · doi:10.1177/1177932219839402 · Cited by 55
RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors
Yuan, X., Tang, Z., Du, R., Yao, Z., Cheung, S., Zhang, X., Wei, J., Zhao, Y., Du, Y., Liu, Y., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12698 · Cited by 39
“However, inhibition of MEK alone so far has very limited success in patients with K-RAS -mutated cancers (Blumenschein et al ., 2015; Caunt et al ., 2015).”
Self-citationLY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells
Ma, Y., Xu, R., Liu, X., Zhang, Y., Li, S., Qiu, X., Cai, S., Zhou, S., Xie, Y., Li, A., et al. (2021) · International Journal of Medical Sciences · doi:10.7150/ijms.51256 · Cited by 40
“Raf and MEK inhibitors were approved and used clinically[17-18].”
MethodA structural perspective on targeting the RTK /Ras/ MAP kinase pathway in cancer
Heppner, D. E., & Eck, M. J. (2021) · Protein Science · doi:10.1002/pro.4125 · Cited by 43
“Despite their common binding site, allosteric MEK inhibitors vary considerably in their efficacy the context of differing mechanisms of pathway activation.(18) While FIGURE 5 Allosteric MEK inhibitors.”
BackgroundSigaud, R., Albert, T., Hess, C. C., Hielscher, T., Winkler, N., Kocher, D., Walter, C., Münter, D., Selt, F., Usta, D., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40235-8 · Cited by 43
MYC and RAF: Key Effectors in Cellular Signaling and Major Drivers in Human Cancer
Stefan, E., & Bister, K. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_4 · Cited by 44
“MEK1/2 serve as critical gatekeeper kinases for ERK1/2 which regulate multiple cellular events through phosphorylation of over 150 substrates in the cytoplasm and nucleus, many involved in cell proliferation and survival (Yoon and Seger 2006; Roskoski 2012b; Caunt et al. 2015; Lake et al. 2016).”
BackgroundInfluentialLiu, Z., Wang, M., Wang, H., Fang, L., & Gou, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01223 · Cited by 41
Weinberg, F., Griffin, R., Fröhlich, M., Heining, C., Braun, S. L., Spohr, C., Iconomou, M., Hollek, V., Röring, M., Horak, P., et al. (2019) · Oncogene · doi:10.1038/s41388-019-1021-1 · Cited by 40
Blocking STAT3 signaling augments MEK/ERK inhibitor efficacy in esophageal squamous cell carcinoma
Zheng, Z.-Y., Chu, M.-Y., Lin, W., Zheng, Y.-Q., Xu, X., Chen, Y., Liao, L., Wu, Z., Wang, S., Li, E., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04941-3 · Cited by 40
“Both MAPK and STAT3 signaling pathways are activated downstream of EGFR [16, 44].”
BackgroundTumor and Systemic Immunomodulatory Effects of MEK Inhibition
Dennison, L., Mohan, A. A., & Yarchoan, M. M. (2021) · Current Oncology Reports · doi:10.1007/s11912-020-01008-4 · Cited by 39
“Since the first synthetic small-molecule inhibitor of MEK1 and MEK2 kinase activity was described in 1995, four small-molecule MEK inhibitors have been approved by the FDA for clinical use in various settings—trametinib, cobimetinib, binimetinib, and selumetinib—and multiple other MEK inhibitors are in clinical or pre…”
BackgroundCuesta, R., & Holz, M. K. (2016) · Oncotarget · doi:10.18632/oncotarget.8375 · Cited by 37
“Interestingly, inhibition of RSKs does not affect the proliferation of normal breast epithelial cells, which suggests that therapeutic RSK inhibition may not produce the adverse side effects associated with MEK inhibitors [6, 40].”
BackgroundLai, H., Zhao, X., Qin, Y., Ding, Y., Chen, R., Li, G., Labrie, M., Ding, Z., Zhou, J., Hu, J., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0696-4 · Cited by 36
“More importantly, new drugs that inhibit MEK are currently undergoing late-stage clinical evaluation [46].”
BackgroundNovoplansky, O., Shnerb, A. B., Marripati, D., Jagadeeshan, S., Shareb, R. A., Conde‐López, C., Zorea, J., Prasad, M., Lulu, T. B., Yegodayev, K. M., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13500 · Cited by 37
“In particular, the PI3K pathway stands out as a major resistance mechanism to MEK inhibition [54], which aligns with our findings.”
BackgroundExploiting receptor tyrosine kinase co-activation for cancer therapy
Tan, A. C., Vyse, S., & Huang, P. H. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.07.010 · Cited by 39
“MEK inhibitors have shown efficacy in a number of different cancer types and are currently being evaluated in advanced clinical trials (61).”
BackgroundRao, G., Kim, I.-K., Conforti, F., Liu, J., Zhang, Y.-W., & Giaccone, G. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.05.013 · Cited by 34
GBP3 promotes glioma cell proliferation via SQSTM1/p62-ERK1/2 axis
Xu, H., Sun, L., Zheng, Y., Yu, S., Ouyang, J., Han, H., Dai, X., Yu, X., Li, M., & Lan, Q. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.11.050 · Cited by 37
Hata, A. N., Rowley, S., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Ji, F., Jung, J., Light, M., Lee, J. S., Debussche, L., et al. (2017) · Oncogene · doi:10.1038/onc.2017.258 · Cited by 34
Lulli, D., Carbone, M., & Pastore, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102227 · Cited by 34
“Since the discovery of the first ERK experimental inhibitor PD98059 20 years ago [8], new MEK inhibitors occupying highly specific allosteric sites of the target molecules have provided the opportunity to achieve higher selectivity and have also contributed to validate MEK as a cancer drug target [9].”
BackgroundLong-term dynamics of multisite phosphorylation
RUBINSTEIN, B. Y., Mattingly, H. H., Berezhkovskii, A. M., & Shvartsman, S. Y. (2016) · Molecular Biology of the Cell · doi:10.1091/mbc.e16-03-0137 · Cited by 38
“For instance, activating mutations in MEK can lead to both developmental abnormalities and cancers, and drugs directly inhibiting MEK are being used in the clinic (Anastasaki et al., 2009; Caunt et al., 2015; Jindal et al., 2015).”
BackgroundThe limitations of targeting MEK signalling in Glioblastoma therapy
Selvasaravanan, K.-D., Burkert, N., Hadzalic, A., Strobel, H., Payer, C., Schuster, A., Karpel‐Massler, G., Siegelin, M. D., Halatsch, M., Debatin, K., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-64289-6 · Cited by 33
Hanrahan, A. J., Sylvester, B. E., Chang, M. T., Elzein, A., Gao, J., Han, W., Liu, Y., Xu, D. H., Gao, S. P., Gorelick, A. N., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0865 · Cited by 36
Ryan, A., Liu, J., & Deiters, A. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c04324 · Cited by 34
The mechanism of activation of MEK1 by B-Raf and KSR1
Maloney, R., Zhang, M., Liu, Y., Jang, H., & Nussinov, R. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04296-0 · Cited by 34
“These MEKi, however, can lead to increased signaling through parallel pathways controlled by non-Raf MEK activators, including the c-Jun N-terminal kinase (JNK), p38, ERK5, and nuclear factor-κB (NF-κB) pathways [44].”
BackgroundFMRP modulates the Wnt signalling pathway in glioblastoma
Pedini, G., Buccarelli, M., Bianchi, F., Pacini, L., Cencelli, G., D’Alessandris, Q. G., Martini, M., Giannetti, S., Sasso, F., Melocchi, V., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05019-w · Cited by 37
“Among the transcription factors regulated by ERK1/2 and involved in cell proliferation, CREB and ETS1 are known to modulate malignant features of glioma cells [63] controlling transcription of GBM genes [64, 65].”
BackgroundThe Role of ERK Signaling in Experimental Autoimmune Encephalomyelitis
Birkner, K., Wasser, B., Loos, J., Plotnikov, A. N., Seger, R., Zipp, F., Witsch, E., & Bittner, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091990 · Cited by 35
“Phosphorylation of the SPS sequence is necessary for binding of ERK to Importin 7 [43].”
MethodResultInfluentialTargeting O-GlcNAcylation in cancer therapeutic resistance: The sugar Saga continues
Chen, L., Hu, M., Chen, L., Peng, Y., Zhang, C., Wang, X., Li, X., Yao, Y., Song, Q., Li, J., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216742 · Cited by 39
Deng, X., Yang, Z., Chan, K. W., Ismail, N., & Bakar, M. Z. A. (2024) · Antioxidants · doi:10.3390/antiox13091030 · Cited by 35
“The inhibition of MAP2K2 may suppress not only the formation of colon cancer but also the progression of colon cancer and its metastasis to the liver and lung [84,85].”
Yang, P., Dong, F., & Zhou, Q. (2017) · Toxicology Letters · doi:10.1016/j.toxlet.2017.06.010 · Cited by 32
Ji, S., Sun, R., Xu, K., Man, Z., Ji, J., Pu, Y., Yin, L., Zhang, J., & Pu, Y. (2019) · Toxicology in Vitro · doi:10.1016/j.tiv.2019.05.003 · Cited by 33
MEK1 regulates pulmonary macrophage inflammatory responses and resolution of acute lung injury
Long, M. E., Gong, K.-Q., Eddy, W. E., Volk, J. S., Morrell, E. D., Mikacenic, C. R., West, T. E., Skerrett, S. J., Charron, J., Liles, W. C., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.132377 · Cited by 34
“Pleschka S, et al. Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade.”
BackgroundInfluentialBilal, F., Arenas, E. J., Pedersen, K., Martínez-Sabadell, A., Nabet, B., Guruceaga, E., Vicent, S., Tabernero, J. M., Macarulla, T. M., & Arribas, J. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-4263 · Cited by 32
“Different MAP kinase pathways cross-talk with the MEK1/2– ERK1/2 pathway (10).”
BackgroundInfluentialKotani, H., Adachi, Y., Kitai, H., Tomida, S., Bando, H., Faber, A. C., Yoshino, T., Voon, D. C., Yano, S., & Ebi, H. (2018) · Oncogene · doi:10.1038/s41388-017-0035-9 · Cited by 35
Neri, L., Lasa, M., Elósegui-Artola, A., D’Avola, D., Carte, B., Gázquez, C., Alve, S., Roca‐Cusachs, P., Iñarrairaegui, M., Herrero, J. I., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17332 · Cited by 31
“The actin cytoskeleton is implicated in the control of numerous signaling pathways that govern cell proliferation [38].”
BackgroundSelumetinib: a selective MEK1 inhibitor for solid tumor treatment
Hedayat, M., Jafari, R., & Zolbanin, N. M. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-021-00783-z · Cited by 36
“Mutations or alterations in molecules of upstream like RAS, RAF, NF1, or MEK in MAPK pathway may be responsible for ERK reactivation [84, 85].”
BackgroundNucleic acid combinations: A new frontier for cancer treatment
Remant Bahadur, K. C., Thapa, B., Valencia‐Serna, J., Aliabadi, H. M., & Uludağ, H. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.04.029 · Cited by 32
Sonic Hedgehog Signaling in Thyroid Cancer
Xu, X., Lu, Y., Li, Y., & Prinz, R. A. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00284 · Cited by 32
ERK Activity Imaging During Migration of Living Cells In Vitro and In Vivo
Hirata, E., & Kiyokawa, E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030679 · Cited by 30
“In turn, activated RAS triggers a phosphorylation cascade consisting of RAF-MEK-ERK (extracellular signal-regulated kinase) [1].”
BackgroundDrug Screening with Genetically Encoded Fluorescent Sensors: Today and Tomorrow
Potekhina, E. S., Bass, D. Y., Kelmanson, I. V., Fetisova, E. S., Ivanenko, A. V., Belousov, V. V., & Bilan, D. S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010148 · Cited by 31
Galvin, R. T., Watson, A. L., Largaespada, D. A., Ratner, N., Osum, S. H., & Moertel, C. L. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01032-y · Cited by 31
Metadata
- Authors
- Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J.
- Affiliations
- University of Bath (GB)
- Babraham Institute (GB)
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Smith, Paul D.
- Cook, Simon J.
- Venue
- Nature Reviews Cancer
- Published
- 2015-09-24
- Volume
- 15
- Issue
- 10
- Pages
- 577-592
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1848470479
- Cited by
- 606
- References
- 201
- Citations by year
- 2026: 27 · 2025: 44 · 2024: 61 · 2023: 48 · 2022: 69 · 2021: 73 · 2020: 47 · 2019: 62 · 2018: 70 · 2017: 66 · 2016: 33 · 2015: 4
- FWCI
- 5.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cancer Research UK (14867)
- Biotechnology and Biological Sciences Research Council (BBS/E/B/0000C199, BBS/E/B/000C0417, BBS/E/B/0000H248, BBS/E/B/000C0419, BBS/E/B/0000H151)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- MEK1 inhibitor, ERK signaling, Raf/MEK/ERK pathway, BRAF mutation, RAS mutations, Raf-1, drug resistance mechanisms, carcinogenesis, cancer therapy
- MeSH terms
- Humans, Neoplasms, Signal Transduction, MAP Kinase Signaling System, Protein Kinase Inhibitors, MAP Kinase Kinase 1, MAP Kinase Kinase 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.